M S Duh1, A M Walker, K H Kronlund. 1. Department of Epidemiology, Harvard School of Public Health, 677 Huntington Avenue, Boston, MA 02115, USA. MeiSheng.Duh@astra-pharmaceuticals.com
Abstract
OBJECTIVES: This study quantifies the incidence of liver enzyme abnormalities in the general population of central Massachusetts. METHODS: Computerized data files from a health maintenance organization were used to ascertain potential subjects during the study period of 1 July 1992-30 June 1993. Medical records and laboratory tests results were reviewed to confirm the diagnoses. RESULTS: The incidence rates were 40.6 cases per 100,000 persons per year for drug-associated liver enzyme abnormalities, 39.0 per 100,000 persons per year for liver enzyme abnormalities secondary to biliary pathologies, 25.2 per 100,000 persons per year for liver enzyme abnormalities secondary to mononucleosis, 25.2 per 100,000 persons per year for liver enzyme abnormalities of unknown aetiology, 15.4 per 100,000 persons per year for alcoholic liver enzyme abnormalities, 12.2 per 100,000 persons per year for liver malignancy, and 7.3 per 100,000 persons per year for viral hepatitis (HAV, HBV and HCV). Men were more commonly affected by alcoholic liver enzyme abnormalities and viral hepatitis, with respective incidence rates approximately 5 and 2 times higher than women. Liver enzyme abnormalities secondary to mononucleosis occurred predominantly between the ages of 15-24 years. In contrast, liver diseases secondary to biliary pathologies, liver malignancies and drug-associated liver enzyme abnormalities were found most frequently among the elderly. CONCLUSION: Liver enzyme abnormalities occurred with a higher incidence in this general population than reported previously in selected patients. Drug-associated liver enzyme abnormality was the most common type. The magnitude of drug-associated liver enzyme abnormality could be much higher as an appreciable proportion of the liver cases of unknown aetiology are potentially drug-attributable. Copyright 1999 John Wiley & Sons, Ltd.
OBJECTIVES: This study quantifies the incidence of liver enzyme abnormalities in the general population of central Massachusetts. METHODS: Computerized data files from a health maintenance organization were used to ascertain potential subjects during the study period of 1 July 1992-30 June 1993. Medical records and laboratory tests results were reviewed to confirm the diagnoses. RESULTS: The incidence rates were 40.6 cases per 100,000 persons per year for drug-associated liver enzyme abnormalities, 39.0 per 100,000 persons per year for liver enzyme abnormalities secondary to biliary pathologies, 25.2 per 100,000 persons per year for liver enzyme abnormalities secondary to mononucleosis, 25.2 per 100,000 persons per year for liver enzyme abnormalities of unknown aetiology, 15.4 per 100,000 persons per year for alcoholic liver enzyme abnormalities, 12.2 per 100,000 persons per year for liver malignancy, and 7.3 per 100,000 persons per year for viral hepatitis (HAV, HBV and HCV). Men were more commonly affected by alcoholic liver enzyme abnormalities and viral hepatitis, with respective incidence rates approximately 5 and 2 times higher than women. Liver enzyme abnormalities secondary to mononucleosis occurred predominantly between the ages of 15-24 years. In contrast, liver diseases secondary to biliary pathologies, liver malignancies and drug-associated liver enzyme abnormalities were found most frequently among the elderly. CONCLUSION:Liver enzyme abnormalities occurred with a higher incidence in this general population than reported previously in selected patients. Drug-associated liver enzyme abnormality was the most common type. The magnitude of drug-associated liver enzyme abnormality could be much higher as an appreciable proportion of the liver cases of unknown aetiology are potentially drug-attributable. Copyright 1999 John Wiley & Sons, Ltd.
Authors: Carmen Ferrajolo; Katia M C Verhamme; Gianluca Trifirò; Geert W 't Jong; Carlo Giaquinto; Gino Picelli; Alessandro Oteri; Sandra de Bie; Vera E Valkhoff; Martijn J Schuemie; Giampiero Mazzaglia; Claudio Cricelli; Francesco Rossi; Annalisa Capuano; Miriam C J M Sturkenboom Journal: Drug Saf Date: 2013-10 Impact factor: 5.606
Authors: Mark E Bangs; Ling Jin; Shuyu Zhang; Durisala Desaiah; Albert J Allen; Holly A Read; Arie Regev; Joachim F Wernicke Journal: Drug Saf Date: 2008 Impact factor: 5.606
Authors: Peter T Donnan; David McLernon; Douglas Steinke; Stephen Ryder; Paul Roderick; Frank M Sullivan; William Rosenberg; John F Dillon Journal: BMC Health Serv Res Date: 2007-04-16 Impact factor: 2.655
Authors: Philip N Newsome; Rob Cramb; Suzanne M Davison; John F Dillon; Mark Foulerton; Edmund M Godfrey; Richard Hall; Ulrike Harrower; Mark Hudson; Andrew Langford; Anne Mackie; Robert Mitchell-Thain; Karen Sennett; Nicholas C Sheron; Julia Verne; Martine Walmsley; Andrew Yeoman Journal: Gut Date: 2017-11-09 Impact factor: 23.059